Composition comprising ketone body and nicotinamide adenine dinucleotide modulator and methyl donor
The present invention provides a composition comprising a mixture of an exogenous ketone body, an exogenous NAD modulator and a methyl donor. Typically, exogenous NAD modulator is an exogenous nicotinamide adenine dinucleotide (NAD) precursor. The present invention also provides a method of using such a composition for treating various clinical conditions, including metabolic disorders and neurocognitive impairments. The compositions of the invention can also be used to improve human performance in various competitive or environmental conditions.
1. A composition comprising a therapeutically effective amount of:
(i) an exogenous ketone body, wherein the ketone body comprises an ester of BHB;
(ii) an exogenous nicotinamide adenine dinucleotide (“NAD”) modulator; and
(iii) betaine in an amount from 0.001 mg to 5,000 mg, wherein the ratio (w/w) of the exogenous ketone body to the exogenous NAD modulator is from 160:1 to 10:1.
2. The composition of claim 1 , wherein the exogenous ketone body is present in the composition in an amount from 1 mg to 50,000 mg.
3. The composition of claim 1 , wherein the betaine is present in the composition in an amount from 150 mg to 1500 mg.
4. The composition of claim 1 , wherein a ratio (w/w) of the exogenous NAD modulator to betaine ranges from 0.25:1 to 6.667:1.
5. The composition of claim 1 , wherein the ratio (w/w) between the exogenous ketone body and the NAD modulator is between 1,000,000:1 and 1000:1.
6. The composition of claim 1 , wherein the ester of BHB is of the formula:
wherein
each of R 6 , R 7 , and R 8 is independently selected from the group consisting of hydrogen, BHB moiety or an acyl group;
provided at least one of R 6 , R 7 , and R 8 is BHB moiety of the formula —C(═O)CH 2 CH(OR 2 )CH 3 , wherein R 2 is H or a hydroxyl protecting group.
7. The composition of claim 1 , wherein the exogenous NAD modulator is nicotinoyl riboside, nicotinamide riboside, nicotinic acid mononucleotide, nicotinamide mononucleotide, β-nicotinamide ribose monophosphate, or a combination thereof.
8. The composition of claim 7 , wherein the exogenous NAD modulator is nicotinamide riboside, and wherein the nicotinamide riboside comprises a protecting group comprising an acetyl group (CH3C(═O)—), an acetoacetyl group, formate, benzoate, or carbamate.
9. The composition of claim 1 , wherein the exogenous NAD modulator is present in the composition in an amount from 0.001 mg to 5,000 mg.
10. The composition of claim 1 , wherein the exogenous NAD modulator is present in the composition in an amount from 125 mg to 2000 mg.
11. The composition of claim 1 , wherein the composition is in a single unit form for administration to a human.
12. The composition of claim 11 , further comprising a carrier.
13. The composition of claim 12 , wherein the carrier is a liquid.
14. The composition of claim 12 , wherein the composition is an emulsion, syrup, aqueous solution, or aqueous suspension.
15. The composition of claim 12 , wherein the carrier comprises one or more of propylene glycol, lecithin, sorbitan monooleate, acacia, thickening agents, natural or synthetic gums, resins, methylcellulose, flavors, sweeteners, colorants, or sodium carboxymethylcellulose.
16. The composition of claim 12 , wherein the composition is a solid.
17. The composition of claim 16 , wherein the composition is formulated as a powder, tablet, pill, capsule, cachet, lozenge, or as dispersible granules.
18. The composition of claim 16 , wherein the composition comprises one or more of a diluent, flavoring agent, solubilizer, lubricant, suspending agent, binder, preservative, tablet disintegrating agent, or encapsulating material.
19. The composition of claim 6 , wherein:
the exogenous NAD modulator is nicotinoyl riboside, nicotinamide riboside, nicotinic acid mononucleotide, nicotinamide mononucleotide, β-nicotinamide ribose monophosphate, or a combination thereof, wherein the exogenous NAD modulator is present in the composition in an amount from 0.001 mg to 5,000 mg.
20. The composition of claim 19 , wherein betaine is present in the composition in an amount from 150 mg to 1500 mg.
21. The composition of claim 20 , wherein the ratio (w/w) of the exogenous NAD modulator to betaine ranges from 0.25:1 to 6.667:1.
22. The composition of claim 19 , wherein the composition is in a single unit form for administration to a human.
23. The composition of claim 19 , wherein the exogenous NAD modulator is present in the composition in an amount from 125 mg to 2000 mg.
24. The composition of claim 19 , wherein the exogenous ketone body is present in the composition in an amount from 1 mg to 50,000 mg.